Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up

Table 4 Incidence of new-onset diabetes according to the number of metabolic syndrome components during the 3-year follow-up

Number of metabolic syndrome components	Incidence of new-onset diabetes		HR (95% CI)	p-value
Number of metabolic syndrome components	Pitavastatin 1 mg	Pitavastatin 4 mg	HR (95% CI)	p-value
1	4/50	1/51	0.23 (0.03, 2.13)	0.20
2	5/96	4/100	0.75 (0.20, 2.91)	0.69
3	4/73	2/74	0.48 (0.09, 2.70)	0.40
4	1/32	2/26	2.58 (0.22, 30.20)	0.45
Overall	14/251	9/251	0.67 (0.27, 1.64)	0.38

ISSN: 1475-2840